INBX ▲ +3.7% - Inhibrx Biosciences, Inc. $INBX - Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study Inhibrx shares rose 3.7% after the company announced it will host a webcast to present primary endpoint results from its Phase 2 study of INBRX-106 as a first-line treatment for head and neck squamous cell carcinoma. Investors typically view the announcement of positive clinical trial readouts as a positive catalyst for biotech companies, particularly when results are being highlighted to the public. 04-SEP-2026 04:01 PM ET